ClinicalTrials.gg
RecruitingNCT06480760CIPHERUpdated Nov 17, 2026

Effects of Carnosine In Patients With Peripheral Arterial Disease Patients

A Phase 1/2 interventional study of Carnosine in Peripheral Arterial Disease, sponsored by Shahid Baba. Recruiting at 3 sites in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Shahid Baba · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.
Updated Nov 17, 2026Enrollment updatedEligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 479 studies in Peripheral Arterial Disease with a site in United States — 82 open to participants now, 101 under way, 10 of them phase 3. Peripheral Arterial Disease · United States.

Planned enrollment
126th of 373
120 · median 64
Started
2025
with 21 others
Phase 1/2
13 of 479
2 open now
Primary completion
2028-10
later than 73 of 100 live
Registered
443rd of 479
by date

Among the 479 studies in Peripheral Arterial Disease with a site in United States, this one is the 126th largest by planned enrollment of the 373 interventional ones that give a count, is one of 22 that started in 2025, is one of 13 in phase 1/2, reaches primary completion later than 73 of the 100 other live ones, and was the 443rd registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

82 of the 479 studies in Peripheral Arterial Disease with a site in United States are open now. Recruiting first, the newest first:

76 more — sign in →

All 82 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 479 studies in Peripheral Arterial Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether carnosine (a food ingredient found in chicken and red meat) supplementation (2 g) for 6 months in participants with non-claudication and claudication peripheral arterial disease (PAD) improves walking ability. Previous studies with heart failure patients have shown that carnosine supplementation increases walking capacity in these patients.

Read the detailed description

The objective of this double-blinded longitudinal study is to determine whether carnosine supplementation (2 g) for 6 months in participants with non-claudication and claudication peripheral arterial disease (PAD) improves walking ability. In this pilot study we will enroll 144 participants that will be divided into placebo (n=60) and carnosine groups (n=60). We will measure the distance covered on the 6-minute walk test (6-MWT) and the pain free walking capacity on the treadmill before and after the placebo or carnosine supplementation. We will measure ankle branchial index (ABI) and blood flow by magnetic resonance imaging (MRI) before and after the carnosine and placebo supplementation. In addition, we will measure carnosine by 1HMRS (Proton magnetic resonance spectroscopy), perform, global metabolomics and proteomics in the skeletal muscle, a comprehensive lipid and metabolic profile of blood, uptake of carnosine in red blood cells (RBCs), and measure carnosine aldehyde conjugates in the urine before and after 6 months of carnosine and placebo supplementation. Following completion of the study, we will follow the participants for another 3 months and examine the durability of carnosine supplementation.

03

Conditions studied

  • Peripheral Arterial Disease

Keywords

  • peripheral arterial disease
  • carnosine
04

Who can participate

The criteria were revised on the registry on Nov 17, 2026. See what changed

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants between 40-80 yrs of age.
  2. White or African American race, irrespective of Hispanic or non-Hispanic ethnicity Literate in English.
  3. ABI >0.4-\<0.90, obtained within 3 months from enrollment.
  4. Willing and able to comply with protocol requirements.
  5. Participant can provide .

Exclusion criteria

Exclusion criteria

  1. Participants with positive test for active Human Immunodeficiency (), active chronic /C/T virus, significant liver disease characterized by or AST>3-5 times higher than the normal range, or total >3-5 times higher than the normal range, anemia having \<8.0 g/dL, end stage renal disease requiring chronic hemodialysis, or chronic renal replacement therapy, lung disease requiring home oxygen therapy, Parkinson disease that impairs walking ability, alcohol or drug abuse, increase in angina or angina at rest, end stage heart failure greater than class III , and active cancer will be excluded.
  2. Critical limb ischemia with below or above the knee amputations or any form of leg ulceration over the symptomatic leg or using walking aid.
  3. Presence of significant injury within 30 days and having an active or incompletely healed wounds, ulcers, gangrene, or vascular intervention on the symptomatic leg within 6 months before enrollment.
  4. Participants with a baseline 6MWT of \< 122 meters (400ft) or > 488 meters (1600ft).
  5. Known allergy to L-carnosine.
  6. Currently participating in other clinical trials.
  7. Participants already taking carnosine.
  8. Participants unable to provide urine sample (anuric).
  9. Pregnant participants.
  10. Participants using warfarin will not be included for .
  11. Participants with MR incompatible internal metallic objects in body will not be eligible for MRI or 1HMRS.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
120 participants (estimated)

Study arms

  • No intervention
    Placebo

    Cellulose

  • Experimental
    Carnosine

    Carnosine 2 g daily for 6 months

    Drug: Carnosine

Interventions

06

What researchers measure

Primary outcomes

  1. Measure distance covered on six-minute walk test (6MWT)

    Distance covered on a flat and hard surface in 6 minutes. Units: Feet

    Time frame: Baseline, 3 months, 6 months, 9 months

Secondary outcomes

  1. Measure Ankle-Brachial Index (ABI)

    Ratio of blood pressure measurements from the arms and ankles. Units: Normal range 1.0-1.4 and lower than 0.9 is an indication of peripheral arterial disease

    Time frame: Baseline, 3 months, 6 months, 9 months

  2. Treadmill Testing

    Graded treadmill testing using the Gardener protocol until the onset of the maximal claudication pain. Units: Meters

    Time frame: Baseline, 3 months, 6 months

  3. Skin Integrity

    Check the color, trophic changes and flakes. Units: None

    Time frame: Baseline, 3 months, 6 months

  4. Musculoskeletal Assessment

    Perform goniometric measurements, assess pain and conduct muscle strength testing. Upper limb muscle strength will be evaluated by hand-grip test and lower limb muscle strength will be evaluated by using a dynamometer. Units: Visual analog scale (VAS 0-10); 0-10 corresponds to the no pain to severe pain.

    Time frame: Baseline, 3 months, 6 months

  5. Neuromuscular Assessment

    For neuromuscular assessment assess the sharp-dull and deep pressure sensation. Units: None

    Time frame: Baseline, 3 months, 6 months

  6. Balance Assessment

    Balance assessment will be measured by Berg balance assessment. Units: Scale 0 to 4, with 4 indicating normal and 0 representing severe impairment

    Time frame: Baseline, 3 months, 6 months

  7. Quality of life Questionnaire

    Health related quality of life using a Short-Form 36 general health survey. Units: An arbitrary scale 0 to 100, with higher scores representing better health.

    Time frame: Baseline, 3 months, 6 months, 9 months

  8. Assessment of PAD Severity

    To assess the leg symptoms, participants who are affirmative for the pain in legs or buttock on walking will be characterized by the responses to San Diego Claudication Questionnaire (SDCQ) and Walking Impairment Questionnaire (WIQ) Measures: (1) intermittent claudication, (2) leg pain on exertion and rest, (3) atypical exertional leg pain, (4) atypical exertional leg pain/stop, and (5) no exertional pain.

    Time frame: Baseline, 3 months, 6 months, 9 months

  9. Depressive Symptoms Questionnaire

    Depression symptoms will be evaluated using Patient Health Questionnaire-9 (PHQ-9). Units: Scores evaluated on a 4-point scale from "not at all" to "nearly every day". PHQ-9 scores of 5, 10, 15, and 20 represented mild, moderate, moderately severe, and severe depression respectively.

    Time frame: Baseline, 3 months, 6 months, 9 months

  10. 24-hour Dietary Recall

    Recall of participant's dietary patterns over the past 24 hours from the time of the visit using web-based, Automated Self-Administered 24-hour (ASA24®) Dietary Assessment Tool 2024 Version.

    Time frame: Baseline, 3 months, 6 months, 9 months

  11. Daily Walking Ability

    Steps over a period of 6 days using triaxial pedometer. Units: step counts

    Time frame: -7-Baseline, Day 90-97, Day 180-187, Day 270-277

  12. Blood Collection and Analysis

    White blood cells, red blood cells. Units: Cells per cubic millimeter. Neutrophils, lymphocytes, monocytes, eosinophils, basophils. Units: percent

    Time frame: Baseline, 3 months, 6 months, 9 months

  13. Blood Collection and Analysis

    Sodium, phosphate, chloride, calcium, glucose, creatinine, albumin, ALT and AST Units: mg/dL

    Time frame: Baseline, 3 months, 6 months, 9 months

  14. Measurement of Carnosine in Blood and Urine

    Using mass spectrometry will measure carnosine bioavailability. Units: moles

    Time frame: Baseline, 3 months, 6 months, 9 months

  15. Measure Angiogenic Cell Population

    Flow cytometry: measure angiogenic cell population. Units: Number of cells

    Time frame: Baseline, 3 months, 6 months, 9 months

  16. Mitochondrial Abundance Measurements

    Perform RTPCR to measure expression of different mitochondrial genes. Units: Relative mRNA expression

    Time frame: Baseline, 3 months, 6 months, 9 months

  17. Measurement of Carnosine in Muscle

    Using magnetic resonance spectroscopy, will measure carnosine accumulation before and after supplementation. Units: millimole.

    Time frame: Baseline, 6 months

  18. Measurement of Blood Flow

    Using magnetic resonance imaging will measure blood flow in the legs. Units: mL/min

    Time frame: Baseline, 6 months

  19. Calf Muscle Biopsy

    Optional muscle biopsy will be obtained by a trained vascular surgeon from the consistent location of medial gastrocnemius of the symptomatic leg using a ¼ inch bore percutaneous biopsy needle.

    Time frame: Baseline, 6 months

07

Study locations

1 of 3 sites recruiting
  • University of Louisville School of Medicine, Department of Medicine, Division of Environmental Medicine
    Louisville, Kentucky 40202, United States
    Recruiting
  • University Surgical Associates, 401 E. Chestnut St, Suite 710
    Louisville, Kentucky 40202, United States
    Not yet recruiting
  • UofL Physicians - Vascular Surgery Associates, 201 Abraham Flexner Way, Suite 1004
    Louisville, Kentucky 40202, United States
    Not yet recruiting
08

References and documents

Publications

  • de Courten B, Jakubova M, de Courten MP, Kukurova IJ, Vallova S, Krumpolec P, Valkovic L, Kurdiova T, Garzon D, Barbaresi S, Teede HJ, Derave W, Krssak M, Aldini G, Ukropec J, Ukropcova B. Effects of carnosine supplementation on glucose metabolism: Pilot clinical trial. Obesity (Silver Spring). 2016 May;24(5):1027-34. doi: 10.1002/oby.21434. Epub 2016 Apr 4. PubMed 27040154 ↗
  • Vincent KA, Shyu KG, Luo Y, Magner M, Tio RA, Jiang C, Goldberg MA, Akita GY, Gregory RJ, Isner JM. Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor. Circulation. 2000 Oct 31;102(18):2255-61. doi: 10.1161/01.cir.102.18.2255. PubMed 11056102 ↗
  • Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation. 1995 Mar 1;91(5):1472-9. doi: 10.1161/01.cir.91.5.1472. PubMed 7867189 ↗
  • Waeckel L, Mallat Z, Potteaux S, Combadiere C, Clergue M, Duriez M, Bao L, Gerard C, Rollins BJ, Tedgui A, Levy BI, Silvestre JS. Impairment in postischemic neovascularization in mice lacking the CXC chemokine receptor 3. Circ Res. 2005 Mar 18;96(5):576-82. doi: 10.1161/01.RES.0000159389.55544.20. Epub 2005 Feb 17. PubMed 15718500 ↗
  • Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D, Betsholtz C. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol. 2003 Jun 23;161(6):1163-77. doi: 10.1083/jcb.200302047. Epub 2003 Jun 16. PubMed 12810700 ↗
  • Creager MA, Olin JW, Belch JJ, Moneta GL, Henry TD, Rajagopalan S, Annex BH, Hiatt WR. Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication. Circulation. 2011 Oct 18;124(16):1765-73. doi: 10.1161/CIRCULATIONAHA.110.009407. Epub 2011 Sep 26. PubMed 21947297 ↗
  • Wang GL, Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood. 1993 Dec 15;82(12):3610-5. PubMed 8260699 ↗
  • Silvestre JS, Mallat Z, Tedgui A, Levy BI. Post-ischaemic neovascularization and inflammation. Cardiovasc Res. 2008 May 1;78(2):242-9. doi: 10.1093/cvr/cvn027. Epub 2008 Feb 5. PubMed 18252762 ↗
  • Aicher A, Zeiher AM, Dimmeler S. Mobilizing endothelial progenitor cells. Hypertension. 2005 Mar;45(3):321-5. doi: 10.1161/01.HYP.0000154789.28695.ea. Epub 2005 Jan 17. PubMed 15655116 ↗
  • Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, Inai Y, Silver M, Isner JM. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999 Jul 15;18(14):3964-72. doi: 10.1093/emboj/18.14.3964. PubMed 10406801 ↗
  • Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996 Sep;16(9):4604-13. doi: 10.1128/MCB.16.9.4604. PubMed 8756616 ↗
  • Ziello JE, Jovin IS, Huang Y. Hypoxia-Inducible Factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia. Yale J Biol Med. 2007 Jun;80(2):51-60. PubMed 18160990 ↗
  • Heil M, Schaper W. Influence of mechanical, cellular, and molecular factors on collateral artery growth (arteriogenesis). Circ Res. 2004 Sep 3;95(5):449-58. doi: 10.1161/01.RES.0000141145.78900.44. PubMed 15345667 ↗
  • Serrano Hernando FJ, Martin Conejero A. [Peripheral artery disease: pathophysiology, diagnosis and treatment]. Rev Esp Cardiol. 2007 Sep;60(9):969-82. doi: 10.1157/13109651. Spanish. PubMed 17915154 ↗
  • Chez MG, Buchanan CP, Aimonovitch MC, Becker M, Schaefer K, Black C, Komen J. Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders. J Child Neurol. 2002 Nov;17(11):833-7. doi: 10.1177/08830738020170111501. PubMed 12585724 ↗
  • Hobson RM, Saunders B, Ball G, Harris RC, Sale C. Effects of beta-alanine supplementation on exercise performance: a meta-analysis. Amino Acids. 2012 Jul;43(1):25-37. doi: 10.1007/s00726-011-1200-z. Epub 2012 Jan 24. PubMed 22270875 ↗
  • Parkhouse WS, McKenzie DC, Hochachka PW, Ovalle WK. Buffering capacity of deproteinized human vastus lateralis muscle. J Appl Physiol (1985). 1985 Jan;58(1):14-7. doi: 10.1152/jappl.1985.58.1.14. PubMed 3968004 ↗
  • Beebe HG, Dawson DL, Cutler BS, Herd JA, Strandness DE Jr, Bortey EB, Forbes WP. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med. 1999 Sep 27;159(17):2041-50. doi: 10.1001/archinte.159.17.2041. PubMed 10510990 ↗
  • Harwood AE, Smith GE, Cayton T, Broadbent E, Chetter IC. A Systematic Review of the Uptake and Adherence Rates to Supervised Exercise Programs in Patients with Intermittent Claudication. Ann Vasc Surg. 2016 Jul;34:280-9. doi: 10.1016/j.avsg.2016.02.009. Epub 2016 Apr 25. PubMed 27126713 ↗
  • Treat-Jacobson D, McDermott MM, Bronas UG, Campia U, Collins TC, Criqui MH, Gardner AW, Hiatt WR, Regensteiner JG, Rich K; American Heart Association Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Council on Cardiovascular and Stroke Nursing. Optimal Exercise Programs for Patients With Peripheral Artery Disease: A Scientific Statement From the American Heart Association. Circulation. 2019 Jan 22;139(4):e10-e33. doi: 10.1161/CIR.0000000000000623. No abstract available. PubMed 30586765 ↗
  • Treat-Jacobson D, McDermott MM, Beckman JA, Burt MA, Creager MA, Ehrman JK, Gardner AW, Mays RJ, Regensteiner JG, Salisbury DL, Schorr EN, Walsh ME; American Heart Association Council on Peripheral Vascular Disease; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; and Council on Lifestyle and Cardiometabolic Health. Implementation of Supervised Exercise Therapy for Patients With Symptomatic Peripheral Artery Disease: A Science Advisory From the American Heart Association. Circulation. 2019 Sep 24;140(13):e700-e710. doi: 10.1161/CIR.0000000000000727. Epub 2019 Aug 26. PubMed 31446770 ↗
  • McDermott MM, Guralnik JM, Tian L, Zhao L, Polonsky TS, Kibbe MR, Criqui MH, Zhang D, Conte MS, Domanchuk K, Li L, Sufit R, Leeuwenburgh C, Ferrucci L. Comparing 6-minute walk versus treadmill walking distance as outcomes in randomized trials of peripheral artery disease. J Vasc Surg. 2020 Mar;71(3):988-1001. doi: 10.1016/j.jvs.2019.05.058. Epub 2019 Dec 23. PubMed 31870756 ↗
  • McDermott MM, Dayanidhi S, Kosmac K, Saini S, Slysz J, Leeuwenburgh C, Hartnell L, Sufit R, Ferrucci L. Walking Exercise Therapy Effects on Lower Extremity Skeletal Muscle in Peripheral Artery Disease. Circ Res. 2021 Jun 11;128(12):1851-1867. doi: 10.1161/CIRCRESAHA.121.318242. Epub 2021 Jun 10. PubMed 34110902 ↗
  • McDermott MM, Spring B, Tian L, Treat-Jacobson D, Ferrucci L, Lloyd-Jones D, Zhao L, Polonsky T, Kibbe MR, Bazzano L, Guralnik JM, Forman DE, Rego A, Zhang D, Domanchuk K, Leeuwenburgh C, Sufit R, Smith B, Manini T, Criqui MH, Rejeski WJ. Effect of Low-Intensity vs High-Intensity Home-Based Walking Exercise on Walk Distance in Patients With Peripheral Artery Disease: The LITE Randomized Clinical Trial. JAMA. 2021 Apr 6;325(13):1266-1276. doi: 10.1001/jama.2021.2536. PubMed 33821898 ↗
  • Money SR, Herd JA, Isaacsohn JL, Davidson M, Cutler B, Heckman J, Forbes WP. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg. 1998 Feb;27(2):267-74; discussion 274-5. doi: 10.1016/s0741-5214(98)70357-x. PubMed 9510281 ↗
  • Dawson DL, Cutler BS, Meissner MH, Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation. 1998 Aug 18;98(7):678-86. doi: 10.1161/01.cir.98.7.678. PubMed 9715861 ↗
  • Girolami B, Bernardi E, Prins MH, Ten Cate JW, Hettiarachchi R, Prandoni P, Girolami A, Buller HR. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med. 1999 Feb 22;159(4):337-45. doi: 10.1001/archinte.159.4.337. PubMed 10030306 ↗
  • Peacock JM, Keo HH, Duval S, Baumgartner I, Oldenburg NC, Jaff MR, Henry TD, Yu X, Hirsch AT. The incidence and health economic burden of ischemic amputation in Minnesota, 2005-2008. Prev Chronic Dis. 2011 Nov;8(6):A141. Epub 2011 Oct 17. PubMed 22005634 ↗
  • Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, McDermott MM, Meigs JB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Rosamond WD, Sorlie PD, Stafford RS, Turan TN, Turner MB, Wong ND, Wylie-Rosett J; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation. 2011 Feb 1;123(4):e18-e209. doi: 10.1161/CIR.0b013e3182009701. Epub 2010 Dec 15. PubMed 21160056 ↗
  • Boakye AA, Zhang D, Guo L, Zheng Y, Hoetker D, Zhao J, Posa DK, Ng CK, Zheng H, Kumar A, Kumar V, Wempe MF, Bhatnagar A, Conklin DJ, Baba SP. Carnosine Supplementation Enhances Post Ischemic Hind Limb Revascularization. Front Physiol. 2019 Jul 2;10:751. doi: 10.3389/fphys.2019.00751. eCollection 2019. PubMed 31312142 ↗
  • Schon M, Just I, Krumpolec P, Blazicek P, Valkovic L, Aldini G, Tsai CL, De Courten B, Krssak M, Ukropcova B, Ukropec J. Supplementation-induced change in muscle carnosine is paralleled by changes in muscle metabolism, protein glycation and reactive carbonyl species sequestering. Physiol Res. 2023 Mar 8;72(1):87-97. doi: 10.33549/physiolres.934911. Epub 2022 Dec 22. PubMed 36545878 ↗
  • Caruso J, Charles J, Unruh K, Giebel R, Learmonth L, Potter W. Ergogenic effects of beta-alanine and carnosine: proposed future research to quantify their efficacy. Nutrients. 2012 Jul;4(7):585-601. doi: 10.3390/nu4070585. Epub 2012 Jun 26. PubMed 22852051 ↗
  • Harris RC, Stellingwerff T. Effect of beta-alanine supplementation on high-intensity exercise performance. Nestle Nutr Inst Workshop Ser. 2013;76:61-71. doi: 10.1159/000350258. Epub 2013 Jul 25. PubMed 23899755 ↗
  • Hipkiss AR. Energy metabolism, proteotoxic stress and age-related dysfunction - protection by carnosine. Mol Aspects Med. 2011 Aug;32(4-6):267-78. doi: 10.1016/j.mam.2011.10.004. Epub 2011 Oct 15. PubMed 22020113 ↗
  • Teufel M, Saudek V, Ledig JP, Bernhardt A, Boularand S, Carreau A, Cairns NJ, Carter C, Cowley DJ, Duverger D, Ganzhorn AJ, Guenet C, Heintzelmann B, Laucher V, Sauvage C, Smirnova T. Sequence identification and characterization of human carnosinase and a closely related non-specific dipeptidase. J Biol Chem. 2003 Feb 21;278(8):6521-31. doi: 10.1074/jbc.M209764200. Epub 2002 Dec 6. PubMed 12473676 ↗
  • Drozak J, Veiga-da-Cunha M, Vertommen D, Stroobant V, Van Schaftingen E. Molecular identification of carnosine synthase as ATP-grasp domain-containing protein 1 (ATPGD1). J Biol Chem. 2010 Mar 26;285(13):9346-9356. doi: 10.1074/jbc.M109.095505. Epub 2010 Jan 22. PubMed 20097752 ↗
  • Lombardi C, Carubelli V, Lazzarini V, Vizzardi E, Bordonali T, Ciccarese C, Castrini AI, Dei Cas A, Nodari S, Metra M. Effects of oral administration of orodispersible levo-carnosine on quality of life and exercise performance in patients with chronic heart failure. Nutrition. 2015 Jan;31(1):72-8. doi: 10.1016/j.nut.2014.04.021. Epub 2014 May 10. PubMed 25287762 ↗
  • Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res. 2015 Apr 24;116(9):1509-26. doi: 10.1161/CIRCRESAHA.116.303849. PubMed 25908725 ↗
  • Annex BH. Therapeutic angiogenesis for critical limb ischaemia. Nat Rev Cardiol. 2013 Jul;10(7):387-96. doi: 10.1038/nrcardio.2013.70. Epub 2013 May 14. PubMed 23670612 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Oct 2028, 40 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2024
First posted
Jun 28, 2024
StartActual
May 20, 2025
Primary completionEst.
Oct 1, 2028
CompletionEst.
Oct 1, 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
144→120
Nov 17, 2026
Eligibility
4 inclusion criteria edited, 1 removed; 6 exclusion criteria edited, 2 removed
What changed in the criteria
Inclusion criteria
  • EditedParticipants between 40-80 yearsyrs of age.
  • EditedWhite or African American race, irrespective of Hispanic or non-Hispanic ethnicity Literate in English.
  • RemovedLiterate in English.
  • EditedABI >0.4-<0.90, obtained within 6 weeks3 months from enrollment.
  • EditedParticipant is able tocan provide informed consent.
Exclusion criteria
  • ChangedBefore As per physician's discretion, participants with HIV, hepatitis, significant liver disease, anemia, renal disease requiring dialysis, lung disease requiring home oxygen therapy, and active cancer may be excluded.Now Participants with positive test for active Human Immunodeficiency (HIV), active chronic hepatitis B/C/T virus, significant liver disease characterized by ALT or AST>3-5 times higher than the normal range, or total bilirubin >3-5 times higher than the normal range, anemia having hemoglobin <8.0 g/dL, end stage renal disease requiring chronic hemodialysis, or chronic renal replacement therapy, lung disease requiring home oxygen therapy, Parkinson disease that impairs walking ability, alcohol or drug abuse, increase in angina or angina at rest, end stage heart failure greater than class III NYHA, and active cancer will be excluded.
  • EditedCritical limb ischemia with below or above the knee amputations or any form of footleg ulceration over the symptomatic leg or using walking aid.
  • EditedPresence of significant injury within 30 days and having an active or incompletely healed wounds, ulcers, gangrene, or vascular intervention on the symptomatic leg within 6 months before enrollment, as per physician's discretion.
  • EditedParticipants with a baseline 6MWT of less than 152.0< 122 meters (498ft400ft) or greater than 487.7> 488 meters (1600ft).
  • RemovedParticipants with rare autosomal recessive metabolic disorder carnosinemia or carnosinase deficiency.
  • RemovedParticipation in any carnosine supplementation clinical trial anytime in the past.
  • EditedParticipants using dual antiplatelet therapieswarfarin will not be included for biopsy.
  • EditedParticipants with MR incompatible internal metallic objects in body will not be eligible for MRI or 1HMRS.
Nov 17, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • University of Louisville School of Medicine, Department of Medicine, Division of Environmental Medicine · Louisville, United StatesContact •••7713→•••4274
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Enrollment 144→120
    Eligibility 4 inclusion criteria edited, 1 removed; 6 exclusion criteria edited, 2 removed
    What changed in the criteria
    Inclusion criteria
    • EditedParticipants between 40-80 yearsyrs of age.
    • EditedWhite or African American race, irrespective of Hispanic or non-Hispanic ethnicity Literate in English.
    • RemovedLiterate in English.
    • EditedABI >0.4-<0.90, obtained within 6 weeks3 months from enrollment.
    • EditedParticipant is able tocan provide informed consent.
    Exclusion criteria
    • ChangedBefore As per physician's discretion, participants with HIV, hepatitis, significant liver disease, anemia, renal disease requiring dialysis, lung disease requiring home oxygen therapy, and active cancer may be excluded.Now Participants with positive test for active Human Immunodeficiency (HIV), active chronic hepatitis B/C/T virus, significant liver disease characterized by ALT or AST>3-5 times higher than the normal range, or total bilirubin >3-5 times higher than the normal range, anemia having hemoglobin <8.0 g/dL, end stage renal disease requiring chronic hemodialysis, or chronic renal replacement therapy, lung disease requiring home oxygen therapy, Parkinson disease that impairs walking ability, alcohol or drug abuse, increase in angina or angina at rest, end stage heart failure greater than class III NYHA, and active cancer will be excluded.
    • EditedCritical limb ischemia with below or above the knee amputations or any form of footleg ulceration over the symptomatic leg or using walking aid.
    • EditedPresence of significant injury within 30 days and having an active or incompletely healed wounds, ulcers, gangrene, or vascular intervention on the symptomatic leg within 6 months before enrollment, as per physician's discretion.
    • EditedParticipants with a baseline 6MWT of less than 152.0< 122 meters (498ft400ft) or greater than 487.7> 488 meters (1600ft).
    • RemovedParticipants with rare autosomal recessive metabolic disorder carnosinemia or carnosinase deficiency.
    • RemovedParticipation in any carnosine supplementation clinical trial anytime in the past.
    • EditedParticipants using dual antiplatelet therapieswarfarin will not be included for biopsy.
    • EditedParticipants with MR incompatible internal metallic objects in body will not be eligible for MRI or 1HMRS.
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University of Louisville School of Medicine, Department of Medicine, Division of Environmental Medicine · Louisville, United StatesContact •••7713→•••4274
    + 3 other changes: verification date, description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06480760
Lead sponsor
Shahid Baba
Responsible party
Shahid Baba (Professor, University of Louisville) — Sponsor-investigator
First posted
Jun 28, 2024
Start date
May 20, 2025
Primary completion
Oct 1, 2028 (estimated)
Completion
Oct 1, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Shahid Baba, PhD
Contact
shahid.baba@louisville.edu
502-296-7713
Amit Dwivedi, MD
Contact
amit.dwivedi@louisville.edu
502-583-8303
Shahid Baba, PhD
principal investigator · University of Louisville School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Carnosine

Start the discussion